Skip to main content
. 2017 Mar 2;3(6):793–800. doi: 10.1001/jamaoncol.2016.6120

Figure 2. Survival Outcomes.

Figure 2.

The 5-year and 10-year survival rates are shown. Patients censored are indicated by a short vertical line on the graph line. T+CEF indicates 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil; TX-CEX, 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine.